Detalhe da pesquisa
1.
HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
J Biol Chem
; 289(30): 20526-42, 2014 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24872420
2.
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
J Virol
; 86(22): 12105-14, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22933284
3.
Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
PLoS One
; 13(4): e0196370, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29689099
4.
Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
PLoS One
; 7(8): e43903, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22928048
5.
Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.
J Virol
; 80(2): 821-34, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16378984
6.
Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.
Virology
; 353(1): 68-82, 2006 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16806384